A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease. by Boyer-Diaz, Zoe et al.
nutrients
Article
A Nutraceutical Rich in Docosahexaenoic Acid
Improves Portal Hypertension in a Preclinical Model
of Advanced Chronic Liver Disease
Zoe Boyer-Diaz 1 , Joan Carles Domingo 2 , Estefanía De Gregorio 3, Nicolò Manicardi 4,
Peio Aristu-Zabalza 1 , Begoña Cordobilla 2 , Laia Abad-Jordà 4, Martí Ortega-Ribera 4,
Anabel Fernández-Iglesias 4,5, Montserrat Marí 3 , Jaime Bosch 4,5,6 and
Jordi Gracia-Sancho 1,4,5,6,*
1 Barcelona Liver Bioservices, 08036 Barcelona, Spain
2 Biochemistry and Molecular Biomedicine Department, Faculty of Biology, University of Barcelona,
08036 Barcelona, Spain
3 Department of Cell Death and Proliferation, IIBB-CSIC/IDIBAPS, 08036 Barcelona, Spain
4 Liver Vascular Biology Research Group, IDIBAPS, 08036 Barcelona, Spain
5 CIBEREHD, 28029 Madrid, Spain
6 Hepatology, Department of Biomedical Research, University of Bern, 3012 Bern, Switzerland
* Correspondence: jordi.gracia@idibaps.org
Received: 29 August 2019; Accepted: 29 September 2019; Published: 3 October 2019


Abstract: Inflammation and oxidative stress play a key role in the pathophysiology of advanced chronic
liver disease (ACLD) and portal hypertension (PH). Considering the current lack of effective treatments,
we evaluated an anti-inflammatory and antioxidant nutraceutical rich in docosahexaenoic acid (DHA)
as a possible therapy for ACLD. We investigated the effects of two-week DHA supplementation
(500 mg/kg) on hepatic fatty acids, PH, oxidative stress, inflammation, and hepatic stellate cell
(HSC) phenotype in rats with ACLD. Additionally, the effects of DHA were evaluated in murine
macrophages and human HSC. In contrast to vehicle-treated animals, cirrhotic rats receiving DHA
reestablished a healthy hepatic fatty acid profile, which was associated with an improvement in PH.
The mechanisms underlying this hemodynamic improvement included a reduction in oxidative stress
and inflammation, as well as a marked HSC deactivation, confirmed in human HSC. Experiments
with cultured macrophages showed that treatment with DHA protects against pro-inflammatory
insults. The present preclinical study demonstrates that a nutraceutical rich in DHA significantly
improves PH in chronic liver disease mainly by suppressing inflammation and oxidative stress-driven
HSC activation, encouraging its evaluation as a new treatment for PH and cirrhosis.
Keywords: DHA; omega-3; liver fibrosis; liver cirrhosis; hepatic hemodynamics
1. Introduction
Advanced chronic liver disease (ACLD) constitutes an important clinical problem worldwide,
causing 1.03 million deaths per year [1]. Unfortunately, current therapeutic options to treat ACLD
are limited, with a lack of effective and safe treatments targeting the main mechanisms mediating the
disease and its complications [2,3].
Alcohol abuse, viral infection, and metabolic factors are some of the main causes of ACLD.
Continuous exposure to these harmful agents causes liver cells to deteriorate and die, releasing signals
which, in turn, lead to severe hepatic inflammation and oxidative stress. In this environment, hepatic
stellate cells (HSC) shift to their activated state and begin an abnormally high deposition of extracellular
matrix, causing liver fibrosis [4,5]. In addition, liver sinusoidal endothelial cells (LSEC) undergo a
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capillarization process, losing their characteristic fenestrae and developing a basal membrane, which
interferes with the communication between sinusoidal blood and parenchymal cells [6]. Altogether, the
ensuing parenchymal and sinusoidal dysfunction contributes to the development of portal hypertension
(PH). PH is considered ACLD’s main complication and becomes clinically significant (associated with
the risk of potentially lethal clinical complications) when the hepatic venous pressure gradient increases
over 10 mmHg. At advanced stages, PH can ultimately lead to bleeding of esophageal varices, ascites
and kidney failure, hepatic encephalopathy, among other serious complications [7].
Previous studies have shown that ω-3 and ω-6 polyunsaturated fatty acid (PUFA) levels are
deregulated during liver disease [8–10]. However, the role of hepatic fatty acids, which may have
severe effects on hepatocyte viability, inflammation, and survival, in the context of ACLD is still
poorly understood. Docosahexaenoic acid (DHA) is an ω-3 essential fatty acid that cannot be
synthesized by the human body and must be obtained from the diet. It is known that ω-3 PUFAs,
and DHA in particular, possess strong anti-inflammatory and antioxidant properties. Its pleiotropic
effects are complex and include the activation of antioxidant pathways, inflammation resolution
by pro-resolving lipid mediators such as resolvins and protectins, increased leukocyte migration,
inhibition of pro-inflammatory cytokines and eicosanoid synthesis, decreased lipid peroxidation,
and regulation of key transcription factors such as nuclear factor kappa B (NFκB) and peroxisome
proliferator-activated receptor gamma (PPAR-γ), among others [11,12]; altogether suggesting that
DHA supplementation could have beneficial effects in ACLD.
In this study, we aimed, in the first place, at characterizing the hepatic fatty acid deregulations
that may take place in ACLD. Given the possible nature of these alterations, and taking into account
the anti-inflammatory and antioxidant properties ofω-3 PUFAs, we then proposed a nutraceutical rich
in DHA triglycerides as a possible approach to reestablish a healthy lipid profile and evaluated its
effects on ACLD and PH.
2. Materials and Methods
2.1. Animal Model of Advanced Chronic Liver Disease
Advanced chronic liver disease (ACLD) was induced in male Sprague–Dawley rats (150 g, Janvier)
by administration of thioacetamide (TAA, Sigma) twice per week during a total of 12 weeks. For that
purpose, TAA was dissolved in saline solution at 125 mg/mL and administered intraperitoneally at a
dose of 250 mg/kg body weight, as previously described [13,14]. Healthy male Sprague–Dawley rats
with a similar final body weight (300 g, Janvier) were used as a control.
Animals were maintained in an environmentally controlled animal facility. All procedures were
approved by the Laboratory Animal Care and Use Committee of the University of Barcelona and were
conducted in accordance with the European Community guidelines for the protection of animals used
for experimental and other scientific purposes (EEC Directive 86/609).
2.2. Docosahexaenoic Acid Administration
After the last TAA administration, animals with ACLD underwent a detoxification period of
2–5 days before beginning pharmacological treatment. A total of six healthy rats and 15 cirrhotic
rats were enrolled per group and randomized to receive fish oil enriched in docosahexaenoic acid
(DHA, 500 mg/kg body weight/day, Brudy Technology, patent W2007/071733A3) or a standard vehicle,
used as placebo (1% methylcellulose + 0.05% poloxamer). Both treatments were administered by
gavage, daily, for a total of two weeks. DHA or vehicle was administered by a third person, and
therefore, the investigators administering the drug and performing the experiments were not aware of
the treatment received by the rats. This blinding was maintained until the final analysis of results. No
treatment-related mortality was registered. However, due to technical issues during the subsequent
in vivo hemodynamic studies, the final number of animals per group was n = 6 for healthy rats
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receiving vehicle, n = 6 for healthy rats receiving DHA, n = 11 for cirrhotic rats receiving vehicle, and n
= 14 for cirrhotic rats receiving DHA.
2.3. In Vivo Hemodynamic Analysis
To avoid alterations in splanchnic hemodynamics, animals were food-deprived for 8–12 h previous
to the study. One hour after the last DHA dosage, rats were anesthetized with ketamine hydrochloride
(100 mg/kg body weight; Imalgene 1000; Merial Laboratories) plus midazolam (5 mg/kg body weight;
Laboratorio Reig Jofré), administered intraperitoneally.
To facilitate breathing during anesthesia, a tracheotomy was performed with a p240 catheter
(Portex). Mean arterial pressure (MAP) and heart rate (HR) were measured by cannulating the
femoral artery, and portal pressure (PP) was measured by cannulating the ileocolic vein, both with a
heparinized p50 catheter (Portex) connected to a pressure probe. Portal blood flow (PBF) and superior
mesenteric arterial blood flow (SMABF) were determined with the help of specific non-constrictive
perivascular ultrasonic transit-time flow probes (Transonic Systems Inc., Ithaca, NY, USA). In order
to avoid portal-collateral blood flow, PBF was measured after the splanchnic vein bifurcation, next
to the entrance to the liver. Pressure and flow probes were connected to a PowerLab (4SP) and data
were displayed into a Chart v5.5.6 software file. Hemodynamic parameters were acquired following a
20 min stabilization period [15]. After completion of the hemodynamic study, blood and tissue samples
were collected for molecular and histological determinations.
2.4. Biochemical Analysis
Fatty acid composition in liver tissue was determined by measuring methyl ester levels following
methylation reaction, using the method described by Lepage and Roy [16]. Gas chromatography (GC)
analysis was performed using a Shimadzu GCMS-QP2010 Plus gas chromatograph/mass spectrometer
(Shimadzu) with a Shimadzu AOC-20i autoinjector and a Shimadzu AOC-20s autosampler. The
column used was a Suprawax-280 (Teknokroma). Data were acquired and analyzed with the help
of GCMS solution software. The injector was used in splitless mode and MS ionization mode was
electron ionization.
Fatty acid methyl esters (FAME) were identified through mass spectra by comparing the elution
pattern and relative retention times of FAME with a reference FAME mixture (GLC-744 Nu-Chek Prep.
Inc. Elysian, MN, USA). Results were expressed as molar percentage of total fatty acids. The activity of
fatty acid-associated enzymes was estimated from the concentration ratio of the enzyme product to
its substrate.
Hepatic oxidative stress was determined as superoxide (O2−) levels in liver tissue. Liver samples
were embedded in optimal cutting temperature (OCT) medium (Leica) and sections were incubated
with the fluorescent dye dihydroethidium (Molecular Probes), as previously described [17]. Six fields
from each slide were randomly selected. Images were obtained with a fluorescence microscope and
quantitative analysis was carried out with ImageJ 1.50e software.
Plasma total antioxidant capacity (TAC) was colorimetrically determined with the help of a
Synergy™ H1M, Hybrid Multi-Mode Microplate Reader (BioTek Instruments, Inc., Winooski, VT), as
previously described [18]. Plasma TAC, expressed as µM copper-reducing equivalent values, was
measured using OxiSelect Total Capacity Assay kit (STA-360, Cell Biolabs Inc., San Diego, CA, USA)
following manufacturer’s instructions.
Serum aspartate aminotransferase (AST) and albumin levels were determined through standard
methods at the Hospital Clinic’s core facilities.
2.5. Liver Histology
Liver tissue samples were fixed in 4% formaldehyde (Sigma), embedded in paraffin, sectioned
and stained with 0.1% Sirius Red in picric acid aqueous solution (Sigma). Ten images from each slide
were analyzed using a microscope (Zeiss Axiovert) equipped with a digital camera and the red-stained
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area was quantified using AxioVision software (Zeiss Axiovert). Values are represented by mean of
fibrosis percentage per total area [19].
2.6. Oil Red O Staining
For steatosis assessment, liver tissue samples were embedded in OCT, sectioned, and stained with
Oil red O (Sigma). Fifteen images from each slide were analyzed using a microscope (Zeiss Axiovert)
equipped with a digital camera. Lipid droplets were evaluated as the percentage of red-stained area
per total area, quantified using AxioVision software (Zeiss Axiovert).
2.7. Immunofluorescence
Liver tissue samples were fixed in 4% formaldehyde (Sigma), embedded in paraffin, sectioned,
and processed for immunofluorescence as previously described [20]. Liver sections were incubated
with a primary antibody against CD68 (1:100, MCA341R, Bio-Rad), a secondary Alexa Fluor 555
antibody (1:300, Life technologies), and 40,6-diamino-2-fenilindol (DAPI) (1:1000, Sigma, Kawasaki,
Japan) and mounted in Fluoromount G medium. Fifteen images from each slide were analyzed using a
fluorescence microscope (Olympus BX-41) and quantitative analysis was carried out with ImageJ 1.50e
software. Results are expressed as the percentage of CD68 positive area per total area.
2.8. Cell Culture and Docosahexaenoic Acid Treatment
Primary murine peritoneal macrophages (PMs) from C57BL/6 mice were harvested by peritoneal
lavage using ice-cold Ca2+ and Mg2+-free PBS, after three days of treatment with 3% thioglycolate.
Murine macrophages from the RAW264.7 cell line and PMs were cultured in Roswell Park Memorial
Institute medium (RPMI) supplemented with 10% v/v fetal bovine serum (Reactiva), 2 mM L-glutamine
(Gibco), 100 U/mL penicillin (Reactiva), and 200 µg/mL streptomycin (Reactiva). Both cell types
were exposed to serum free medium for 24 h to obtain quiescent cells before being exposed to
lipopolysaccharide (LPS). RAW264.7 cells were treated with 10 µM DHA or vehicle (ethanol 0.1%–0.5%
v/v) for 72 h, followed by 50 ng/mL LPS or 0.25 mM palmitic acid (PA) for 4 h. Mouse peritoneal
macrophages were treated with 7.5 µM DHA or vehicle for 72 h, followed by 50 ng/mL LPS or 100 ng/mL
tumor necrosis factor alpha (TNFα) for 6 h.
LX-2 human hepatic stellate cells (HSC) were seeded onto p6 plates at a density of 60,000 per plate
in High-Glucose Dulbecco’s Modified Eagle Medium (DMEM, Biological Industries) supplemented
with 10% v/v fetal bovine serum, 4 mM L-glutamine, 100 U/mL penicillin, and 200 µg/mL streptomycin
and cultured for 24 h. Cells were then incubated with increasing concentrations of DHA (10 and 50 µM)
or vehicle (ethanol 0.1%–0.5% v/v) for 72 h.
2.9. RNA Isolation and Quantitative PCR
RNA was extracted from cells and liver tissue using RNeasy mini kit (Qiagen, Hilden, Germany)
and Trizol (Life Technologies, Carlsbad, CA, USA) respectively, and quantified with the help of a
NanoDrop spectrophotometer. Reverse transcription was carried out following QuantiTect reverse
transcription kit (Qiagen). qPCR was performed using PowerUp SYBR Green Master Mix (Thermo
Fisher, Waltham, MA, USA) and the primers are described in Supplementary Table S1. All amplification
reactions were performed as duplicates and nuclease free water was used as a no template control.
Results are expressed as 2−∆∆Ct, relative to the endogenous control GAPDH or β-actin.
2.10. Western Blot Analysis
Triton lysis buffer was used for protein extraction of both LX-2 cells and liver tissue samples.
Nuclear extracts from RAW264.7 cells were isolated as previously described [21]. Proteins were
separated by molecular weight by electrophoresis using a sodium dodecylsulfate polyacrylamide
gel and transferred to a nitrocellulose membrane. To avoid non-specific binding, membranes were
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blocked with Tris-buffered saline containing 0.05% Tween-20 and 3% bovine serum albumin or 5% dry
milk. Membranes were then incubated overnight with primary antibodies, at 4 ◦C and 1 h with the
corresponding horseradish peroxidase-conjugated secondary antibodies, at room temperature [22]. A
complete list of the antibodies used is provided in Supplementary Table S2. Lastly, chemiluminescent
signal levels were detected with a LAS4000 (GE Healthcare, Chicago, IL, USA), and protein expression
was determined by densitometric analysis using the Image Studio Lite software (LI-COR). Results
are expressed as relative densitometric values normalized to endogenous control glyceraldehyde
3-phosphate dehydrogenase (GAPDH) or Lamin A/C.
2.11. Statistical Analysis
Results were analyzed by GraphPad Prism v5.0.0 (GraphPad Software, San Diego, CA, USA).
Data in the figures are expressed as mean ± standard error of the mean (S.E.M.). Differences among
groups were tested for statistical significance by Student’s t test, when comparing two groups, or
by two-way ANOVA followed by post hoc Tukey’s test, when two different factors were involved.
Differences were considered significant at p < 0.05.
3. Results
3.1. Hepatic Fatty Acid Profile Is Deregulated in Rats with ACLD
Rats with ACLD exhibited a profoundly deregulated hepatic fatty acid profile, both structurally
and enzymatically. Compared to healthy rats (Table 1), cirrhotic rats presented higher monounsaturated
fatty acid (MUFA; +55%) and lower polyunsaturated fatty acid levels (PUFA; −14%). In particular,
oleic acid (OA), arachidonic acid (AA), and DHA were notably affected (+187%, −22%, and −66%,
respectively). These alterations led to changed cell membrane characteristics (−36% SFA/MUFA and
−80% PUFA/MUFA ratios), a shift to pro-inflammatory phenotype (+44% AA/EPA and +141% AA/DHA
ratios), and a decrease in ω-3 index (−65%), as shown in Table 2. Moreover, changes in enzymatic
activity were observed, with an increase of SCD18 index (C18:1 n-9/C18:0) and a reduction of elongase
activities (C18:0/C16:0, C24:0/C22:0 and C24:0/C20:0) (Table 2). Altogether, these data indicate that
the pathology increases de novo lipogenesis in the liver and alters FA metabolism, pathways that are
recognized as important contributors to the development of metabolic disorders.
3.2. Treatment with DHA Reestablishes a Healthy Lipid Profile
When treated with DHA, cirrhotic animals presented a remarkable improvement in their hepatic
fatty acid composition, reaching values comparable to those of healthy animals (Table 1). As expected,
rats that received DHA showed higherω-3 and lowerω-6 levels compared to those receiving placebo.
Other fatty acid families also presented changes, such as SFA and MUFA (+8% and −37%, respectively),
with a striking reduction of OA levels (−43%). Membrane characteristics (+68% SFA/MUFA and +80%
PUFA/MUFA ratios) and anti-inflammatory capacity (−94% AA/EPA and −88% AA/DHA ratios) were
recovered, as well as a normal fatty acid enzymatic activity (Table 2). Consequently, there was a specific
raise in elongase activities and as well as a decrease of SCD18 index.
3.3. DHA Ameliorates Portal Hypertension in Rats with ACLD
As shown in Table 3, rats with ACLD receiving DHA exhibited a significant improvement in
portal hypertension (−13.37% in portal pressure in vivo) compared to those receiving vehicle. This
reduction in portal pressure was not accompanied by a decrease in portal blood flow, thus suggesting
an amelioration in intrahepatic vascular resistance (−24.57%). No significant changes were observed in
systemic hemodynamic parameters such as mean arterial pressure and heart rate, or in general features
such as body, liver, and spleen weight (Supplementary Table S3).
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Table 1. Effects of docosahexaenoic acid (DHA) administration on hepatic fatty acid composition in
healthy and cirrhotic rats.
Fatty Acid Healthy Vehicle Healthy DHA Cirrhotic Vehicle Cirrhotic DHA
SFA
MA (14:0) 0.39 ± 0.04 0.31 ± 0.03 0.43 ± 0.01 0.30 ± 0.02 **
PA (C16:0) 21.09 ± 0.31 21.48 ± 0.67 23.28 ± 0.41 ### 24.58 ± 0.39
SA (C18:0) 17.82 ± 0.26 17.40 ± 0.72 14.43 ± 0.88### 16.02 ± 0.54
MUFA
POA (C16:1 n-7) 1.74 ± 0.17 1.68 ± 0.22 2.64 ± 0.30 1.74 ± 2.13 *
OA (C18:1 n-9) 8.40 ± 0.54 7.33 ± 0.40 15.70 ± 1.32 ### 8.87 ± 0.22 ***
VAC (C18:1 n-7) 3.77 ± 0.29 3.03 ± 0.10 3.36 ± 0.16 2.85 ± 0.16
EIA (C20:1 n-9) 0.13 ± 0.01 0.11 ± 0.01 0.12 ± 0.01 0.12 ± 0.01
NA (C24:1 n-9) 0.27 ± 0.02 0.24 ± 0.01 0.29 ± 0.03 0.34 ± 0.03
PUFA
n-3 series
ALA (C18:3 n-3) 0.40 ± 0.04 0.43 ± 0.05 0.40 ± 0.03 0.25 ± 0.02 ***
ETE (C20:3 n-3) 0.30 ± 0,02 0.22 ± 0.02 * 0.28 ± 0.02 0.13 ± 0.02 **
EPA (C20:5 n-3) 0.18 ± 0.03 1.4 ± 0.26 ** 0.11 ± 0.02 1.25 ± 0.08 ***
DPA (C22:5 n-3) 0.59 ± 0.03 1.41 ± 0.16 ** 0.64 ± 0.03 1.42 ± 0.08 ***
DHA (C22:6 n-3) 5.85 ± 0.48 9.82 ± 0.52 ** 1.97 ± 0.25 ### 11.70 ± 0.45 ***
n-6 series
LA (C18:2 n-6) 17.63 ± 0.54 18.37 ± 0.31 18.13 ± 0.42 17.32 ± 0.29
GLA (C18:3 n-6) 0.16 ± 0.01 0.11 ± 0.01 * 0.32 ± 0.02 0.08 ± 0.01 ***
HGLA (C20:3 n-6) 0.52 ± 0.05 0.84 ± 0.05 *** 0.,32 ± 0.02 0.82 ± 0.05 ***
AA (C20:4 n-6) 18.59 ± 0.32 14.76 ± 0.72 *** 14.86 ± 0.90 ### 10.25 ± 0.34 ***
DTA (C22:4 n-6) 0.49 ± 0.02 0.20 ± 0.02 *** 0.73 ± 0.07 0.21 ± 0.01 ***
DPA (C22:5 n-6) 0.26 ± 0.01 0.20 ± 0.02 1.07 ± 0.18 0.24 ± 0.02 ***
Total SFA 40.26 ± 0.54 40.11 ± 0.90 39.01 ± 0.53 42.07 ± 0.35 ***
Total MUFA 14.31 ± 0.93 12.34 ± 0.56 22.11 ± 1.55 ### 13.93 ± 0.36 ***
Total PUFA 45.44 ± 0.97 47.50 ± 0.74 38.88 ± 1.08 ### 43.99 ± 0.37 ***
Total n-3 FA 7.32 ± 0.54 12.94 ± 0.86 *** 3.11 ± 0.24 ### 14.74 ± 0.47 ***
Total n-6 FA 38.11 ± 0.76 34.55 ± 0.65 *** 35.77 ± 0.85 29.26 ± 0.33 ***
Results represent percentage (%) of total fatty acids and are expressed as mean ± S.E.M. n = 5 for healthy animals and
n = 11 for cirrhotic animals. # <0.05; ## <0.01; ### <0.001 vs. healthy vehicle group and * <0.05; ** <0.01; *** <0.001 vs.
corresponding group receiving vehicle. AA, arachidonic acid; ALA, alpha linolenic acid; DHA, docosahexaenoic
acid; DPA, docosapentaenoic acid; DTA, docosatetraenoic acid; EIA, eicosenoic acid; EPA, eicosapentaenoic acid;
ERA, erucic acid; ETE, eicosatrienoic acid; FA, fatty acid; GLA, gamma linoleic acid; HGLA, homogamma linolenic
acid; LA, linoleic acid; MA, myristic acid; MUFA, monounsaturated fatty acid; NA, nervonic acid; OA, oleic acid;
PA, palmitic acid; POA, palmitoleic acid; PUFA, polyunsaturated fatty acid; SA, stearic acid; SFA, saturated fatty
acid; VAC, vaccenic acid.
Table 2. Effects of DHA administration on hepatic fatty acid ratios in healthy and cirrhotic rats.
Ratios HealthyVehicle
Healthy
DHA
Cirrhotic
Vehicle
Cirrhotic
DHA
SFA/MUFA 2.86 ± 0.44 3.27 ± 0.48 1.81 ± 0.34 ### 3.04 ± 0.30 ***
MUFA/PUFA 0.32 ± 0.06 0.26 ± 0.03 0.58 ± 0.13 ## 0.32 ± 0.03 ***
ω-6/ω-3 5.32 ± 0.88 2.72 ± 0.46 ** 11.72 ± 1.56 ### 2.01 ± 0.26 ***
ω-3 INDEX
(DHA + EPA) 6.03 ± 1.09 11.15 ± 1.64 *** 2.08 ± 0.57 ### 12.95 ± 1.49 ***
AA/EPA 108.3 ± 25.2 12.74 ± 5.69 *** 156.0 ± 24.2 ### 8.65 ± 2.35 ***
AA/DHA 3.26 ± 0.58 1.50 ± 0.33 *** 7.87 ± 1.41 ### 0.90 ± 0.18 ***
∆5
(C20:4 n-6/C20:3 n-6) 36.99 ± 3.95 17.39 ± 1.152 *** 47.55 ± 2.12 12.09 ± 0.85 ***
∆6
(C20:3 n-6/C18:2 n-6) 2.99 ± 0.31 4.58 ± 0.27 1.76 ± 0.10 4.76 ± 0.31 ***
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Table 2. Cont.
Ratios HealthyVehicle
Healthy
DHA
Cirrhotic
Vehicle
Cirrhotic
DHA
SCD1 INDEX
(C16:1 n-7/C18:1 n-9) 20.72 ± 1.81 22.98 ± 2.79 16.80 ± 1.33 19.74 ± 1.51
SCD16 INDEX
(C16:1 n-7/C16:0) 8.24 ± 0.81 7.73 ± 0.78 11.30 ± 1.17 7.08 ± 0.49
SCD18 INDEX
(C18:1 n-9/C18:0) 47.32 ± 3.70 42.72 ± 3.76 111.6 ± 14.1 ### 56.02 ± 2.63 ***
C18:2 n-6/C20:4 n-6 0.95 ± 0.02 1.29 ± 0.08 1.24 ± 0.09 1.71 ± 0.08
C18:0/C16:0 0.85 ± 0.01 0.81 ± 0.04 0.62 ± 0.05 # 0.66 ± 0.03
C24:0/C22:0 2.82 ± 0.12 3.39 ± 0.20 2.53 ± 0.22 3.01 ± 0.12
C24:0/C20:0 7.77 ± 0.73 7.28 ± 0.58 3.90 ± 0.35 # 5.73 ± 0.35
C18:1 n-7/C16:1 n-7 2.22 ± 0,18 1.92 ± 0.23 1.34 ± 0.17 1.67 ± 0.11 **
Results are expressed as mean ± S.E.M. n = 5 for healthy animals and n = 11 for cirrhotic animals. # <0.05; ## <0.01;
## <0.001 vs. healthy vehicle group and * <0.05; ** <0.01; *** <0.001 vs. corresponding group receiving vehicle.
AA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PUFA, polyunsaturated fatty acid;
MUFA, monounsaturated fatty acid; SFA, saturated fatty acid.
Table 3. Effects of DHA administration on hepatic and systemic hemodynamics and serum markers in
a rat model of advanced chronic liver disease (ACLD).
Parameter Vehicle DHA p Value
PP (mmHg) 13.91 ± 0.60 12.05 ± 0.57 0.03
PBF (mL·min−1) 15.66 ± 2.54 18.21 ± 2.31 >0.20
IHVR (mmHg·min·mL−1) 1.05 ± 0.15 0.79 ± 0.11 0.16
SMABF (mL·min−1) 8.37 ± 0.91 10.03 ± 1.45 >0.20
MAP (mmHg) 116.23 ± 5.40 99.92 ± 6.25 0.1
HR (beats·min−1) 415 ± 13 383 ± 17 0.15
AST (U/L) 155.8 ± 17.08 115.8 ± 9.05 0.04
Albumin (U/L) 31.2 ± 0.32 30.27 ± 0.53 >0.20
Results are expressed as mean ± S.E.M. n = 11 and n = 14, respectively, for vehicle and DHA. PP, portal pressure;
MAP, mean arterial pressure; PBF, portal blood flow; IHVR, intrahepatic vascular resistance; SMABF, superior
mesenteric arterial blood flow; HR, heart rate; AST, aspartate aminotransferase.
Analysis of serum markers revealed that DHA-treated animals also presented significantly
lower levels of serum aspartate aminotransferase (−25.67%), indicating an improvement of hepatic
necro-inflammation, whereas albumin levels remained unchanged (Table 3).
3.4. DHA Reduces Oxidative Stress and Inflammation
Hepatic and systemic oxidative stress were evaluated as superoxide (O2−) levels in liver tissue and
plasma total antioxidant capacity (TAC), respectively. Rats with ACLD that received DHA presented
significantly lower superoxide levels than those that received vehicle (−20.70%; Figure 1A) as well as a
higher TAC, although this increase did not reach statistical significance (+24.87%, p = 0.1).
Hepatic steatosis, measured as the percentage of oil red O positive area, was significantly decreased
in DHA-treated animals, with a 64.99% reduction of lipid droplets compared to those treated with
vehicle (Figure 1B).
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Figure 1. Effects of DHA on oxidative stress and inflammation in a rat model of ACLD. (A)
Representative images of dihydroethidium staining in liver tissue sections from cirrhotic rats treated
with DHA or vehicle (left—scale bar represents 200µm), and corresponding quantification of superoxide
(O2−) levels (right). (B) Representative images of oil red O staining of liver tissue cryosections from
cirrhotic rats treated with DHA or vehicle (left—scale bar represents 100 µm), and corresponding
quantification (right). (C) Representative images of CD68 immunofluorescence in liver tissue sections
from cirrhotic rats treated with DHA or vehicle (left—scale bar represents 200 µm; CD68 positive cells
in red and nuclei in blue), and corresponding quantification (right). (D) Relative mRNA and (E) protein
expression of key interleukins in total liver tissue from cirrhotic rats treated with DHA or vehicle,
normalized to GAPDH. Results are expressed as mean ± S.E.M. * p < 0.05 and ** p < 0.01 vs. vehicle.
n = 3 per group (A), n = 11 per group (B, C), and n = 10 per group (D,E).
Moreover, cirrhotic animals treated with DHA showed reduced hepatic inflammation compared
to those that received vehicle, with a significantly reduced macrophage infiltration in the liver (−25.69%
CD68 positive area; Figure 1C) and the downregulation of key interleukins (IL) that mediate the
inflammatory response in ACLD (Figure 1D). Particularly, DHA-treated animals showed significantly
reduced IL-1β and IL-10 mRNA expression (−64.68% and −60.97%, respectively), as well as a tendency
to decrease IL-6 expression (−71.63%). At the protein level, this downregulation was even greater,
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with a decrease in expression of 90.99% for IL-1β and 49.85% for IL-6, both statistically significant
(Figure 1E).
To evaluate the protective effect of DHA against pro-inflammatory insults, macrophages pre-treated
with DHA or vehicle were then supplemented with either LPS, TNFα, or PA, agents known to mediate
potent pro-inflammatory responses [23,24].
Murine macrophages from the RAW264.7 cell line treated with DHA presented lower nuclear
levels of NFκB transcription factor than those treated with vehicle, after undergoing lipopolysaccharide
(LPS) or palmitic acid (PA) challenges for 30 min (Figure 2A). Similarly, as shown in Figure 2B,C,
relative mRNA expression of the pro-inflammatory cytokines IL-6 and tumor necrosis factor alpha
(TNFα) was significantly decreased in DHA pre-treated macrophages, compared to vehicle-treated
cells, after 4 h of incubation with either LPS (−95.86% and −83.59%, respectively) or PA (−49.70% and
−44.91%, respectively).
Figure 2. Effects of DHA on macrophage activity. (A) p65-NFκB (nuclear factor kappa B) nuclear
protein expression in murine macrophages from the RAW264.7 cell line treated with DHA (10 µM)
or vehicle and undergoing no challenge, lipopolysaccharide (LPS) challenge or PA challenge. Lamin
A/C expression is shown as a loading control. (B) Interleukin 6 (IL-6) and (C) tumor necrosis factor
alpha (TNFα) relative mRNA expression in murine macrophages from the RAW264.7 cell line treated
with DHA or vehicle and undergoing no challenge, LPS challenge or palmitic acid (PA) challenge,
normalized to β-actin. (D) IL-6, (E) TNFα and (F) Arg1 relative mRNA expression in primary murine
peritoneal macrophages treated with DHA (7.5 µM) or vehicle and undergoing no challenge, LPS
challenge or TNFα challenge, normalized to β-actin. Results are expressed as mean ± S.E.M. * p < 0.05
and ** p < 0.01 vs. vehicle without challenge; † p < 0.05 and †† p < 0.01 vs. vehicle under the same
challenge conditions. n = 4 per group (B,C), and n = 3 per group (D–F).
Primary murine peritoneal macrophages (PMs) isolated from C57BL/6 mice were equally treated
with DHA or vehicle and submitted to LPS and TNFα challenges. IL-6 and TNFαmRNA expression
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after incubation with either LPS (−90.49 and −60.11%, respectively) or TNFα (−83.08% and −72.98%,
respectively) was strongly reduced in DHA-treated macrophages compared to those receiving vehicle
(Figure 2D,E). Contrarily, expression of the anti-inflammatory enzyme arginase was heavily increased
in DHA pre-treated cells both at basal levels (+1171%) and after incubation with LPS (+177.83%) or
TNFα (+633.63%), as shown in Figure 2F. Taken together, these results indicate that, not only does
DHA have anti-inflammatory effects in the liver and systemically, but that it also grants a protective
effect against possible future inflammatory insults.
3.5. DHA Promotes HSC Deactivation in Rats with ACLD
In order to evaluate the effects of DHA on HSC phenotype, expression of activation marker
alpha smooth muscle actin (α-SMA) was determined (Figure 3A,B). Cirrhotic rats that received DHA
presented a striking reduction in α-SMA expression compared to those that received vehicle, both
at mRNA (−78.71%) and protein levels (−57.48%), indicating that DHA strongly promotes HSC
deactivation. Similarly, collagen-1α1 expression was significantly lower in animals treated with DHA,
at mRNA (−48.23%) and protein levels (−48.64%), confirming that HSC deactivation led to a decrease
in extracellular matrix generation.
Figure 3. Effects of DHA on hepatic stellate cell (HSC) phenotype and fibrosis. (A) α-SMA and
collagen-1α1 relative mRNA expression in total liver tissue from cirrhotic rats treated with DHA or
vehicle, normalized to GAPDH. (B) α-SMA and collagen-1α1 relative protein expression in total liver
tissue from cirrhotic rats treated with DHA or vehicle, normalized to GAPDH. (C) Representative
images of Sirius Red staining of liver tissue sections from cirrhotic rats treated with DHA or vehicle
(left—scale bar represents 500 µm), and corresponding quantification (right). (D) α-SMA, TGFβR
and PDGFβR relative protein expression in LX-2 HSCs treated with DHA (10 and 50 µM) or vehicle,
normalized to GAPDH. Results are expressed as mean ± S.E.M. * p < 0.05 and ** p < 0.01 vs. vehicle.
n = 10 per group (A–C), and n = 3 per group (D).
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Liver fibrosis, measured as the percentage of Sirius Red positive area, was slightly lower in
cirrhotic rats that received DHA than in those receiving vehicle (−18%), although this change was not
statistically significant (Figure 3C).
3.6. DHA Promotes Deactivation of Human HSC
To assess whether the DHA-mediated HSC deactivation observed in the animal model of ACLD
may also occur in the human pathology, human LX-2 HSC were treated with increasing concentrations
of DHA. As shown in Figure 3D, DHA promoted HSC deactivation in a concentration-dependent
manner, as demonstrated by a reduction in key activation markers such as α-SMA, transforming
growth factor beta (TGFβ), and platelet derived growth factor receptor beta (PDGFRβ) (data for 50 µM:
−93%, −92%, and −98%, respectively).
4. Discussion
Chronic liver injury involves a variety of mechanisms, parts of which are still undefined. In this
regard, the role of hepatic fatty acids and their possible implication in hepatocyte viability, inflammation,
and survival remains to be elucidated. The present study shows that advanced chronic liver disease
(ACLD) pathophysiology involves a profound deregulation in the hepatic fatty acid profile. Said
deregulation affects both monounsaturated and polyunsaturated fatty acids, with a marked unbalance
in ω-3 and ω-6 essential fatty acids. In particular, docosahexaenoic acid (DHA), known to be a
key regulator of many anti-inflammatory and antioxidant processes, presented strikingly low levels
in comparison to healthy animals, suggesting possible beneficial effects of DHA supplementation
in ACLD. Indeed, treatment with a supplement rich in DHA notably improved hepatic fatty acid
composition in cirrhotic animals, reestablishing control levels of many fatty acids and ameliorating
membrane quality and anti-inflammatory capacity ratios.
Previous studies had suggested beneficial effects of DHA supplementation in models of acute
mild liver injury [25] and non-alcoholic fatty liver disease [26–29]. In the present study, however, we
investigated the effects of DHA in a model of advanced chronic liver disease showing for the first
time that it improves portal hypertension. The reduction in portal pressure was not accompanied
by a reduction in portal blood flow, pointing to a decrease in intrahepatic vascular resistance as the
main mechanism driving this improvement. These results suggest that DHA can have potent effects
in improving liver disease, even at very advanced stages, that go beyond reestablishing the liver’s
lipid profile.
To determine the underlying mechanisms mediating the improvement of portal hypertension,
we evaluated DHA’s effects on oxidative stress, inflammation, hepatic stellate cell (HSC) phenotype,
and fibrosis. As expected, given its well-documented antioxidant and anti-inflammatory
properties [11,12,30,31], cirrhotic animals receiving DHA presented decreased hepatic oxidative
stress and inflammation levels. Moreover, studies performed in cultured murine macrophages showed
that DHA confers a protective effect against pro-inflammatory challenges, reducing drastically the
magnitude of the response.
Furthermore, analysis of HSC phenotype revealed an important HSC deactivation in animals
with ACLD treated with DHA, together with a decrease in extracellular matrix synthesis. Liver tissue
fibrosis, however, failed to show a significant decrease in animals receiving DHA. This inconsistency
between gene/protein expression determinations and liver histology analysis probably stems from
the necessity of a longer period of time to allow extracellular matrix remodeling. Indeed, this is a
complex process that requires the coordination of multiple enzymes to degrade the excessive matrix
accumulation present in such advanced stages of liver disease [32,33], which suggests that a prolonged
treatment with DHA could be more beneficial in reducing hepatic fibrosis. On the other hand, it is well
known that liver vascular resistance is not only dependent on architectural distortion caused by fibrosis
and parenchymal remodeling, but that an increased hepatic vascular tone contributes to further increase
in intrahepatic resistance and portal pressure. This dynamic increase in liver vascular resistance
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has been well characterized and is mainly dependent on the existence of endothelial dysfunction at
the intrahepatic circulation [3]. Intrahepatic endothelial dysfunction denotes a situation where the
liver microcirculation losses its capacity to vasodilate in response to increased blood flow-related
shear stress, is mainly determined by decreased nitric oxide (NO) bioavailability at the intrahepatic
circulation, and aggravated by a shift in eicosanoid metabolism and increased endothelin production.
In ACLD, intrahepatic endothelial dysfunction is multifactorial, and involves defective NO production
due to decreased endothelial nitric oxide synthase (eNOS) activity, insufficient Krüppel-like factor 2
(KLF-2) expression, Rho A–Rho kinase dysregulation, increased asymmetric dimethylarginine (ADMA)
production and, very importantly, NO scavenging by free oxygen radicals due to excessive oxidative
stress [17]. Indeed, the importance of increased oxidative stress in liver endothelial dysfunction and
increased hepatic vascular tone in ACLD has been highlighted by several studies from our group
demonstrating the effectivity of pharmacological and genetic antioxidant and anti-inflammatory
strategies improving portal hypertension and ACLD, at least at the bench side [34–37].
Considering the lack of effective and safe treatments for ACLD at the bedside [2,3], and the
potential benefits described in the herein presented animal model of cirrhosis, we finally evaluated
whether the improvement in rat HSC phenotype could be reproduced in human LX-2 HSC. Human cells
treated with DHA showed a marked deactivation similar to what was observed in the animal model.
These results, therefore, encourage the evaluation of this type of non-pharmacological therapeutic
strategy as a new treatment for portal hypertension and cirrhosis.
In conclusion, the present study shows that ACLD pathophysiology involves a profound
deregulation in the hepatic fatty acid composition. Treatment with a nutraceutical rich in DHA
reestablished a healthy fatty acid profile. Moreover, cirrhotic animals that received DHA presented
a moderate but significant improvement in portal hypertension. The mechanisms underlying this
hemodynamic improvement included a reduction in oxidative stress and inflammation, as well as a
marked HSC deactivation. Said deactivation was confirmed in human HSC, strengthening the interest
of evaluating the use of DHA as a possible nutraceutical therapy for ACLD.
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